Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAGOON Trial: Lurbinectedin vs Investigator's Choice in Relapsed SCLC
NCT05153239Phase 3Completed
- Sponsor
- PharmaMar
- Start
- Jul 2022
- Primary completion
- Apr 2026
- Modality
- Classical Binding Small Molecules, DNA Intercalators/Alkylators
- Countries
- 24
01
Overview
A Phase 3 trial of lurbinectedin in small cell lung cancer (SCLC), sponsored by PharmaMar. Started Jul 2022; status: completed.
02
Drugs
lurbinectedin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05153239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05153239.